Radiopharmaceutical therapy for prostate cancer requires specialized physical infrastructure, staffing and clinical workflows to provide high quality patient care. Moreover, targeted radiopharmaceutical therapy is an emerging cancer treatment modality and continues to evolve rapidly. Without a fundamental understanding of practical considerations for radiopharmaceutical therapy and insight into future directions for the modality, practicing Radiation Oncologists cannot feasibly incorporate radiopharmaceuticals into clinical practice and lead research and development in this novel oncology modality. 

This activity explores topics related to further improving on prostate cancer clinical outcomes with PSMA-directed RPTs including ongoing clinical trials, dosimetry, and combination therapy including with external beam radiotherapy. A discussion of challenging clinical scenarios related to applying 177Lu-PSMA-617 in the clinic is also included.